In line with these preclinical results, we observed in a small French-Canadian cohort of NSCLC patients under immunotherapy targeting PD-1 or PD-L1 (n = 205) that benzodiazepine use correlated with reduced progression-free survival (PFS). Here, PDCD1 is linked to non-small cell lung carcinoma.